Aktieanalys

Alzecure: Pre-IND response received – ACD440 - Redeye

Redeye Publicerad: 09 Feb 2022 09:07

Earlier today, Alzecure reported that the company had received a supportive response from the FDA regarding its pre-IND application for its upcoming phase IIa study with ACD440, Alzecure’s drug candidate addressing neuropathic pain. This further indicates that the timeline to initiate the clinical trial by 2022 is kept. We maintain our positive view of Alzecure (base case SEK 19) and look forward to follow further progress with ACD440.

Länk till analysen i sin helhet: https://www.redeye.se/research/832308/alzecure-pre-ind-response-received-acd440?utm_source=finwire&utm_medium=RSS

Nyheter om AlzeCure Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!